Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib + Everolimus vs Sunitinib in 2L Advanced RCC
NCT07165418Phase 3Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vorolanib in renal cell carcinoma (RCC), sponsored by Peking University Cancer Hospital & Institute. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
vorolanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07165418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165418.